Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hwasun
Clinical trial register · South Korea

Clinical Trials in Hwasun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC6 Regeneron Pharmaceuticals5 GlaxoSmithKline3 Seoul National University Bundang Hospital3 Janssen Research & Development, LLC3
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Hwasun

84 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637Venous Thromboembolism, Active Cancer
DrugsEdoxaban·Apixaban
Samsung Medical Center
Phase 4
2,300
Goyang-si, Busan, Goyang, Gwangmyeong, Hwasun, Jeonju, Seoul
2026-11-01
Not yet open
LucasBio
Phase 1/2
42
Seoul, Daegu, Goyang-si, Hwasun, Ulsan
2026-09-01
Recruiting
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Busan, Hwasun, Seongnam, Seoul
2026-06-24
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Goyang-si, Gyeonggi-do, Hwasun, Seoul
2026-05-31
Recruiting
Samsung Medical Center
Observational
396
Daegu, Daejeon, Seongnam-si, Yangsan, Incheon, Jeju City, Jeonju, Hwasun
2026-05-28
Recruiting
Transition of Care in Pediatric Rare Endocrine Disorders
NCT07786142Endocrine Disorder, Rare Disorders
Seoul National University Hospital
Not applicable
150
Daegu, Daejeon, Gwangju, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2026-05-20
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Seongnam-si, Hwasun, Gyeonggi-do, Seoul
2026-03-12
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
45
Seongnam-si, Hwasun, Busan, Daegu, Daejeon, Seoul
2026-02-12
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Hwasun, Seoul, Ulsan
2026-01-02
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Suwon, Hwasun, Incheon, Seoul
2025-12-17
Recruiting
NOBO Medicine
Phase 1
9
Hwasun, Seongnam, Seoul, Ulsan
2025-12-02
Recruiting
Boehringer Ingelheim
Phase 3
670
Busan, Daejoen, Goyang, Hwasun, Seongnam, Seoul
2025-11-07
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Daejeon, Daegu, Busan-si, Pusan, Ulsan, Namdong, Hwasun, Seoul
2025-09-26
Recruiting
Seoul National University Bundang Hospital
Phase 2
130
Busan, Daegu, Gangneung, Seongnam-si, Incheon, Hwasun, Cheongju-si, Seoul
2025-08-27
Recruiting
Pusan National University Yangsan Hospital
Phase 2
186
Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2025-07-23
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Daegu, Seongnam-si, Hwasun, Seocho, Seoul
2025-07-18
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gyeonggi-do, Cheongju-si, Hwasun, Seoul
2025-05-06
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Busan, Goyang-si, Hwasun, Seongnam, Seoul
2025-01-28
Recruiting
GlaxoSmithKline
Phase 3
520
Hwasun, Jeonju, Seoul, Ulsan
2024-12-16
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Hwasun, Seongnam, Seoul
2024-12-13
Recruiting
Yonsei University
Phase 2
40
Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
2024-12-11
Recruiting
YOUNGIL KOH
Phase 1/2
75
Hwasun, Seoul
2024-11-26
Recruiting
NOBO Medicine
Phase 2
33
Busan, Hwasun, Ilsan, Seongnam, Seoul, Ulsan
2024-11-25
Recruiting
Pfizer
Phase 3
900
Hwasun, Goyang-si, Seoul, Daegu, Junggu
2024-10-22
Active, closed
Pfizer
Phase 3
600
Hwasun, Goyang-si, Seoul, Daegu
2024-10-21
Recruiting
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394Acute Lymphoblastic Leukemia, Pediatric
Hyoung Jin Kang
Phase 2
74
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-10-20
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
Ferring Pharmaceuticals
Phase 3
250
Yangsan, Hwasun, Seoul
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Goyang-si, Yangsan, Hwasun, Seoul
2024-10-01
Active, closed
Merus B.V.
Phase 3
699
Busan, Goyang-si, Hwasun, Seoul, Suwon
2024-09-25
Recruiting
Bristol-Myers Squibb
Observational
15
Hwasun, Seoul
2024-09-11
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Gyeonggi-do, Suwon, Hwasun, Incheon, Seoul, Ulsan
2024-07-16
Active, closed
Merus B.V.
Phase 3
621
Busan, Goyang-si, Hwasun, Seoul, Soeul, Suwon
2024-06-25
Recruiting
Allogene Therapeutics
Phase 2
250
Seogu, Goyang-si, Suwon, Hwasun, Seoul
2024-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul
2024-05-24
Recruiting
Ho Joon Im
Phase 2
90
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-04-04
Recruiting
Hee Young Ju
Phase 2
116
Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon
2024-03-05
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Ansan, Busan, Daegu, Hwasun, Incheon, Jinju, Seongnam, Seoul
2024-01-16
Recruiting
Eli Lilly and Company
Phase 3
1,264
Cheongju-si, Daegu, Deagu, Gangnam-gu, Goyang-si, Hwasun, Seoul, Suwon
2023-12-21
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Seongnam-si, Jinju, Hwasun, Busan, Daegu, Incheon, Seoul
2023-12-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Active, closed
Celgene
Phase 3
79
Hwasun, Seoul
2023-10-16
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsTRK-950·Ramucirumab·Paclitaxel
Toray Industries, Inc
Phase 2
146
Seongnam-si, Hwasun, Daegu, Seoul
2023-10-04
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Incheon, Jeonju, Hwasun, Busan, Seoul
2023-09-18
Recruiting
CrystalGenomics, Inc.
Phase 2
60
Anam, Anyang, Hwasun, Seoul, Yangsan
2023-08-23
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Jungni I Gu, Busan, Hwasun, Seoul
2023-06-01
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
Seoul, Hwasun, Goyang
2023-04-21
Recruiting
Seoul National University Bundang Hospital
Observational
1,240
Daegu, Gyeonggi-do, Hwasun, Ilsan, Jinju, Seongnam-si, Seoul, Yangsan
2023-04-01
By invitation
G7 Dual Mobility With Vivacit-E or Longevity PMCF
NCT05548972Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis
Zimmer Biomet
Not applicable
358
Yangsan, Hwasun
2023-03-20
Recruiting
Fore Biotherapeutics
Phase 2
254
Suwon, Pusan, Hwasun, Seoul
2023-02-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hwasun, Pusan, Daejeon, Seoul
2023-02-06
Recruiting
Seoul National University Hospital
Phase 3
236
Busan, Daegu, Goyang, Hwasun, Seongnam, Seoul, Suwon
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Busan, Goyang-si, Hwasun, Seongnam, Seoul
2022-12-15
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Busan, Daegu, Goyang-si, Hwasun, Incheon, Seoul
2022-10-25
Active, closed
Seoul National University Bundang Hospital
Observational
1,000
Bucheon-si, Chungju, Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju
2022-09-28
Recruiting
Celgene
Phase 3
810
Busan, Seongnam, Hwasun, Seoul
2022-09-20
Active, closed
Exelixis
Phase 3
901
Goyang-si, Gyeonggi-do, Hwasun, Seongnam-si, Seoul
2022-09-07
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
Seoul, Hwasun
2022-08-08
Recruiting
CHA University
Not applicable
240
Cheonan, Ansan-si, Goyang-si, Seongnam-si, Yangsan, Changwon, Hwasun, Busan
2022-08-01
Active, closed
Arcus Biosciences, Inc.
Phase 2
332
Busan, Daegu, Hwasun, Seongnam-si, Seoul, Suwon
2022-06-10
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Jeonju, Daegu, Gyeonggi-do, Hwasun, Seoul
2022-05-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hwasun, Deagu, Daejeon, Seoul
2022-03-24
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Hwasun, Seoul
2022-02-28
Active, closed
Eli Lilly and Company
Phase 3
152
Hwasun, Goyang-si, Seongnam, Busan, Seoul, Deagu
2021-12-20
Active, closed
Amgen
Phase 3
303
Busan, Daejeon, Hwasun, Seoul
2021-11-02
Active, closed
Nuvation Bio Inc.
Phase 2
217
Busan, Gyeongsang, Hwasun, Seoul
2021-09-01
Active, closed
HUYABIO International, LLC.
Phase 3
450
Goyang-si, Seongnam-si, Seoul, Hwasun, Daejeon
2021-08-12
Active, closed
Daiichi Sankyo
Phase 3
490
Daegu, Hwasun, Seongnam, Seoul
2021-05-21
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
Seongnam, Hwasun, Seoul
2021-04-22
Active, closed
Cellbion Co., Ltd.
Phase 1/2
91
Hwasun, Seoul
2021-04-12
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Busan, Seongnam-si, Hwasun, Daegu, Seoul
2021-03-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Hwasun, Seoul
2021-02-25
Active, closed
BioNTech SE
Phase 2/3
358
Hwasun, Seoul, Suwon
2021-01-07
Active, closed
Kyungpook National University Hospital
Phase 3
708
Hwasun, Daegu, Seoul, Suwon
2020-10-23
Active, closed
Exelixis
Phase 3
575
Junggu, Goyang-si, Seongnam-si, Hwasun, Busan, Daegu, Gwangju, Seoul
2020-10-19
Active, closed
GlaxoSmithKline
Phase 3
302
Gyeonggi-do, Hwasun, Inchon, Seoul
2020-10-01
Active, closed
GlaxoSmithKline
Phase 3
325
Gyeonggi-do, Hwasun, Incheon, Seongnam-si Gyeonggi-do, Seoul
2020-04-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Daejeon, Goyang-si, Hwasun, Seongnam-si, Seoul
2020-03-30
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
Gyeonggi-do, Seongnam-si, Suwon, Pusan, Hwasun, Incheon, Cheongju-si, Busan
2020-01-07
Active, closed
Safety and Efficacy of the ANTHEM™ CR Total Knee System
NCT03885622Non-inflammatory Degenerative Joint Disease
Smith & Nephew Pte Ltd
Observational
153
Hwasun, Incheon
2018-11-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Inceon, Hwasun, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Gangnam-gu, Songpagu
2018-08-21
Active, closed
Gilead Sciences
Phase 2
502
Daegu, Goyang-si, Gwangju, Hwasun, Seongbuk-Gu, Seoul, Suwon, Wŏnju
2018-08-13
Active, closed
Kyung Hee University Hospital at Gangdong
Phase 3
358
Busan, Cheonan, Chuncheon, Daegu, Daejeon, Hwasun, Iksan, Seoul
2016-12-07
Active, closed
Geron Corporation
Phase 2/3
289
Seogu, Incheon, Hwasun, Seoul
2016-01-12
Rows per page Showing 1–84 of 84
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/hwasun

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 84 of those studies with a site in Hwasun.

How many clinical trials are recruiting in Hwasun?

44 of the 84 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 37 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hwasun), 84 studies
PhaseStudiesRecruitingShare
Phase 3441952.4%
Phase 2181321.4%
Phase 1/2637.1%
Observational536%
Phase 2/3424.8%
Not applicable323.6%
Phase 1323.6%
Phase 4101.2%

Most active sponsors

Lead sponsors with the most studies (Hwasun)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC62
Regeneron Pharmaceuticals52
GlaxoSmithKline31
Janssen Research & Development, LLC32
Seoul National University Bundang Hospital32
Arcus Biosciences, Inc.20
ArriVent BioPharma, Inc.21
Astellas Pharma Global Development, Inc.21
Bristol-Myers Squibb22
Celgene21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.